title: Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers.
abstract: Chronic obstructive pulmonary disease (COPD) is a multicomponent condition characterized by airway inflammation and associated to comorbidities, including cardiovascular diseases. Among anti-inflammatory agents in development for COPD, the phosphodiesterase inhibitors administrated by inhalation have the potential for increased efficacy and reduced systemic side effects. CHF6001 is an inhaled PDE4 inhibitor with proven anti-inflammatory properties in animal models. This randomized, double-blind, placebo-controlled study was aimed to demonstrate its cardiovascular safety and tolerability in healthy male volunteers with normal electrocardiogram and cardiac parameters. Single and multiple ascending doses (7 days of administration) of CHF6001 were administered. Three electrocardiograms were recorded at several pharmacokinetic time points and at each time points, postdose heart rate, QRS and PR intervals, and presence of arrhythmia were evaluated. In single ascending dose, QTcF intervals did not increase more than 30 milliseconds from the baseline, all heart rate was between 45 and 100 bpm, and no statistically significant differences were observed in PR and QRS intervals. In multiple ascending dose, cardiac parameters did not differ significantly from baseline. In the pharmacokinetic/pharmacodynamic analysis, no medically or clinically significant changes were found. Further studies are ongoing to demonstrate that CHF6001 is safe and well tolerated in COPD patients as well.
authors.affiliation: *Global Clinical Development Department, Chiesi Farmaceutici, Parma, Italy; and †Cardiology Unit, Hopital Bichat University Hospital, Paris, France.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ferrari
authors.forename: Anna
authors.initials: A
authors.lastname: Compagnoni
authors.forename: Anne
authors.initials: A
authors.lastname: Nandeuil
authors.forename: Pierre
authors.initials: P
authors.lastname: Maison-Blanche
mesh_terms: D000200:Action Potentials / Q000187:drug effects*; D000280:Administration, Inhalation; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000503:physiopathology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D015716:Electrocardiography, Ambulatory; D064368:Healthy Volunteers; D006329:Heart Conduction System / Q000187:drug effects* / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D061214:Patient Safety; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D018570:Risk Assessment; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D013997:Time Factors; D062366:para-Aminobenzoates / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: C000596339:tanimilast; D058988:Phosphodiesterase 4 Inhibitors; D013449:Sulfonamides; D062366:para-Aminobenzoates